Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer's Disease Data at J.P. Morgan 2025 Healthcare Conference
Earnings Week Ahead: ORCL, GME, ADBE, COST, AVGO, M and More
Anavex Life Sciences Down Over 13%, On Track for Largest Percent Decrease Since January -- Data Talk
Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024
Buy Recommendation for Anavex Life Sciences: Promising Alzheimer's Treatment and Expanding Clinical Pipeline
Anavex Submits Marketing Authorization Application to EU Regulator for Blarcamesine to Treat Alzheimer's; Shares Jump Pre-Bell
